BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9071515)

  • 21. Efficacy and continuation rates of Norplant in Pakistan.
    Rehan N; Inayatullah A; Chaudhary I
    Contraception; 1999 Jul; 60(1):39-43. PubMed ID: 10549451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continuation rates of long-acting methods of contraception. A comparative study of Norplant implants and intrauterine devices.
    Fleming D; Davie J; Glasier A
    Contraception; 1998 Jan; 57(1):19-21. PubMed ID: 9554246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants.
    Sivin I
    Drug Saf; 2003; 26(5):303-35. PubMed ID: 12650633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Norplant contraceptive implants: rods versus capsules.
    Pasquale SA; Brandeis V; Cruz RI; Kelly S; Sweeney M
    Contraception; 1987 Sep; 36(3):305-16. PubMed ID: 3119287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Norplant contraceptive subdermal implants: one year experience in Singapore.
    Singh K; Viegas OA; Ratnam SS
    Contraception; 1988 May; 37(5):457-69. PubMed ID: 3136971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Norplant subdermal contraceptive system: experience in Taiwan.
    Tseng LH; Lee TY; Yang YS; Ko TM; Chuang SM
    Contraception; 1996 Mar; 53(3):177-80. PubMed ID: 8689883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
    Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
    Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter comparative study on the efficacy, safety, and acceptability of the contraceptive subdermal implants Norplant and Norplant-II.
    del Carmen Cravioto M; Alvarado G; Canto-de-Cetina T; Bassol S; Oropeza G; Santos-Yung R; Valencia J; Palma Y; Fuziwara JL; Navarrete T; Garza-Flores J; Pérez-Palacios G
    Contraception; 1997 Jun; 55(6):359-67. PubMed ID: 9262932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contraceptive outcomes among adolescents prescribed Norplant implants versus oral contraceptives after one year of use.
    Berenson AB; Wiemann CM; Rickerr VI; McCombs SL
    Am J Obstet Gynecol; 1997 Mar; 176(3):586-92. PubMed ID: 9077611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Irregular bleeding, body mass index and coital frequency in Norplant contraceptive users.
    Pasquale SA; Knuppel RA; Owens AG; Bachmann GA
    Contraception; 1994 Aug; 50(2):109-16. PubMed ID: 7956210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma levels of levonorgestrel and free levonorgestrel index in women using NORPLANT implants or two covered rods (NORPLANT-2).
    Olsson SE; Odlind V; Johansson ED; Nordström ML
    Contraception; 1987 Mar; 35(3):215-28. PubMed ID: 3111784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A five-year clinical trial of levonorgestrel silastic implants (Norplant TM).
    Diaz S; Pavez M; Miranda P; Robertson DN; Sivin I; Croxatto HB
    Contraception; 1982 May; 25(5):447-56. PubMed ID: 6809423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
    Luukkainen T; Toivonen J
    Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of Norplant implants in a New York City clinic population.
    Gerber S; Westhoff C; Lopez M; Gordon L
    Contraception; 1994 Jun; 49(6):557-64. PubMed ID: 8070260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three-year experience with NORPLANT subdermal contraception.
    Sivin I; Sanchez FA; Diaz S; Holma P; Coutinho E; McDonald O; Robertson DN; Stern J
    Fertil Steril; 1983 Jun; 39(6):799-808. PubMed ID: 6406273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experience with side effects and health risks associated with Norplant implant use in adolescents.
    Rosenthal SL; Biro FM; Kollar LM; Hillard PJ; Rauh JL
    Contraception; 1995 Nov; 52(5):283-5. PubMed ID: 8585884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Return of fertility following discontinuation of Norplant-II subdermal implants. ICMR Task Force on Hormonal Contraception.
    Buckshee K; Chatterjee P; Dhall GI; Hazra MN; Kodkany BS; Lalitha K; Logambal A; Manchanda P; Nanda UK; RaiChoudhury G
    Contraception; 1995 Apr; 51(4):237-42. PubMed ID: 7796589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hormonal implants: contraception for a new century.
    Darney PD
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1536-43. PubMed ID: 8178903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of Implanon on lipid metabolism in comparison with Norplant.
    Suherman SK; Affandi B; Korver T
    Contraception; 1999 Nov; 60(5):281-7. PubMed ID: 10717780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contraceptive implants.
    Ladipo O; Coutinho EM
    Curr Opin Obstet Gynecol; 1994 Dec; 6(6):564-9. PubMed ID: 7893965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.